BioCentury
ARTICLE | Clinical News

Syndax slides on entinostat PFS miss in breast cancer

October 26, 2018 5:37 PM UTC

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) fell $1.03 (17%) to $5.01 Friday after reporting late Thursday that entinostat missed the primary endpoint of improving progression-free survival in the Phase III E2112 trial to treat breast cancer. The company said the trial will continue as planned to evaluate the other primary endpoint of overall survival (OS).

The oral histone deacetylase (HDAC) inhibitor has breakthrough therapy designation in the U.S. for advanced hormone receptor-positive breast cancer. E2112 evaluated patients treated with exemestane plus either placebo or once-weekly oral entinostat...

BCIQ Target Profiles

Histone deacetylase (HDAC)